Hello, Everyone.

I would like to wish all of our shareholders, global partners, and those who have generously provided support and guidance for the development of our company a healthy and happy new year.

In particular, we apologize and apologize to our shareholders who have made generous investments based on their faith, trust, and innovative technologies.

1) We demonstrated the capabilities of a venture company that developed a world-recognized technology product, but it was not recognized as an innovative technology in Korea, and the president realized that it is almost impossible to meet expectations in a short time by leading changes (innovation) that breaks habits and customs rather than high economic efficiency, because the safety and effectiveness of innovative technologies are superior, overcome human error, and reduce significant workload.

We learned a great lesson that the path to global leadership is not easy in a short time by developing a world-class innovative technology product that failed to overcome the limitations and problems of existing technologies despite decades of medical device history.

2) However, we realized that the way for an innovative venture company to go is to create technology products with unmet needs, and products that meet the absolute needs of customers can fulfill our wishes in a short time. Unmet needs technology products are technology products that overcome difficult tasks that people avoid because they are inconvenient, dangerous, and limited to vertical industries, and we realized that unmet needs technology products in fields that have been impossible due to the limitations of the original technology can fulfill our deepest desires and become a global leader.

In 1), we requested and demoed the system, but in 2), the customer requested and demoed the system, and in 1), the existing global partners including Japan rejected the product, but in 2), the existing global partners and multiple customers in all countries want to trade, and in 1), the global CSTD major company with a market size of 7 trillion won as of 2020 was not interested, but in 2), the global CSTD major company B and I in the United States, Company S from Israel has identified the function and performance of Anyfusion Quick ACPi system at the Korea Hospital Pharmacy Association and requested and promoted strategic collaboration, and 1) there was no country negotiating an exclusive contract including Korea after the international medical device exhibition, but 2) we believe that multiple buyers in multiple countries including Korea are requesting and promoting contracts, which will fulfill our wishes in a short time.

January 2024 Quick ACPi system kit set with cylinder cartridge, which increases CSTD function without using syringe, has almost 100% CSTD function and rapid dispensing performance competitiveness, which is why global major companies are requesting strategic alliance.

In Korea, consumables for dispensing are not paid and cannot be used universally, but the only Anyfusion competitiveness that is paid when the dispensed anti-cancer (injection) drug is injected with the Anyfusion cylinder pump is the high economic efficiency of the hospital and pharmacy dispensing part, and it is judged that the demo of J University Hospital in Jeonbuk, C University Hospital in Chungbuk, and C University Hospital in Chungnam can determine the success of the domestic business.

In developed countries with a market share of more than 90%, where syringe-based CSTD is already a salary, and dispensing without CSTD is unthinkable, disconnection without syringe is minimized by minimizing disconnection without syringe with the Anyfusion Quick ACPi system kit set, a technology that enables performance and rapid dispensing of CSTD, We believe that the January contract in Spain, worth more than 100 billion won, will be a springboard for market expansion not only in Spain but also in Europe as a whole, where the market is expected to grow at an arithmetic as well as an exponential rate with the registration of the item in the European public procurement market.

From January 17th, the Osaka Medical Equipment Exhibition is expected to sign contracts in Japan, the world's second largest market, and from January 29th, Arab Healthcare in Dubai, UAE, is expected to judge the progress of contracts in the Middle East and China.

In the new year, we will do our best to maximize these opportunities and make a splash by realizing your expectations and wishes.

Thank you.